Danaher Corporation (DHR) 10-Year Financial Performance & Capital Metrics

DHR • • Industrial / General

HealthcareDiagnostics & ResearchLife Sciences Instrumentation & ToolsLaboratory Equipment & Consumables

AboutDanaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.Show more

Revenue $23.88B
EBITDA $7.54B +1.2%
Net Income $3.9B -18.2%
EPS (Diluted) 5.29 -17.1%
Gross Margin 59.5% +1.3%
EBITDA Margin 31.56% +1.3%
Operating Margin 21.71% -1.7%
Net Margin 16.33% -18.1%
ROE 7.57% -17.7%
ROIC 5.9% -1.7%
Debt/Equity 0.35 -5.3%
Interest Coverage 18.65 +2.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong Piotroski F-Score: 7/9
✓FCF machine: 22.2% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Healthy 5Y average net margin of 20.3%

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y1.83%

5Y5.92%

3Y-6.76%

TTM2.22%

Profit (Net Income) CAGR

10Y4.14%

5Y8.8%

3Y-15.37%

TTM-9.99%

EPS CAGR

10Y3.84%

5Y9.05%

3Y-14.99%

TTM-7.44%

ROCE

10Y Avg7.78%

5Y Avg8.4%

3Y Avg7.99%

Latest7.06%

Peer Comparison

Laboratory Equipment & Consumables

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
QGENQiagen N.V.	9.97B	48.38	127.32	0.66%	19.58%	11.11%	5.08%	0.40
RVTYRevvity, Inc.	13.08B	115.33	47.85	0.16%	8.47%	3.23%	4.14%	0.43
DHRDanaher Corporation	169.45B	239.89	45.35	-0.06%	14.43%	6.86%	3.13%	0.35
TMOThermo Fisher Scientific Inc.	234.69B	624.65	37.79	0.05%	15.02%	12.84%	3.1%	0.66
WATWaters Corporation	23.5B	394.59	36.84	0.07%	20.89%	27.84%	2.64%	0.93
MTDMettler-Toledo International Inc.	30.57B	1496.61	36.80	2.22%	21.2%		2.83%
AAgilent Technologies, Inc.	41.06B	144.83	31.69	6.73%	18.75%	19.33%	2.81%	0.50
TWSTTwist Bioscience Corporation	2.53B	41.27	-31.75	20.32%	-23.51%	-17.81%		0.16

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	14.43B	16.88B	18.33B	17.05B	17.91B	22.28B	29.45B	26.64B	23.89B	23.88B
Revenue Growth %	-0.28%	0.17%	0.09%	-0.07%	0.05%	0.24%	0.32%	-0.1%	-0.1%	-0%
Cost of Goods Sold+	6.52B	7.5B	8.1B	7.54B	7.93B	9.81B	11.5B	10.46B	9.86B	9.67B
COGS % of Revenue	0.45%	0.44%	0.44%	0.44%	0.44%	0.44%	0.39%	0.39%	0.41%	0.4%
Gross Profit+	7.91B	9.38B	10.23B	9.51B	9.98B	12.47B	17.95B	16.19B	14.03B	14.21B
Gross Margin %	0.55%	0.56%	0.56%	0.56%	0.56%	0.56%	0.61%	0.61%	0.59%	0.6%
Gross Profit Growth %	-0.25%	0.19%	0.09%	-0.07%	0.05%	0.25%	0.44%	-0.1%	-0.13%	0.01%
Operating Expenses+	5.5B	6.4B	7.08B	6.44B	6.62B	8.16B	9.9B	8.65B	8.76B	9.02B
OpEx % of Revenue	0.38%	0.38%	0.39%	0.38%	0.37%	0.37%	0.34%	0.32%	0.37%	0.38%
Selling, General & Admin	4.63B	5.42B	5.95B	5.38B	5.5B	6.82B	8.16B	7.12B	7.25B	7.44B
SG&A % of Revenue	0.32%	0.32%	0.32%	0.32%	0.31%	0.31%	0.28%	0.27%	0.3%	0.31%
Research & Development	861.4M	975.1M	1.13B	1.06B	1.13B	1.35B	1.74B	1.53B	1.5B	1.58B
R&D % of Revenue	0.06%	0.06%	0.06%	0.06%	0.06%	0.06%	0.06%	0.06%	0.06%	0.07%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	2.42B	2.99B	3.15B	3.07B	3.36B	4.31B	8.05B	7.54B	5.28B	5.18B
Operating Margin %	0.17%	0.18%	0.17%	0.18%	0.19%	0.19%	0.27%	0.28%	0.22%	0.22%
Operating Income Growth %	-0.33%	0.24%	0.05%	-0.03%	0.1%	0.28%	0.87%	-0.06%	-0.3%	-0.02%
EBITDA+	3.3B	4.12B	4.39B	4.25B	4.55B	6.09B	10.22B	9.67B	7.45B	7.54B
EBITDA Margin %	0.23%	0.24%	0.24%	0.25%	0.25%	0.27%	0.35%	0.36%	0.31%	0.32%
EBITDA Growth %	-0.27%	0.25%	0.07%	-0.03%	0.07%	0.34%	0.68%	-0.05%	-0.23%	0.01%
D&A (Non-Cash Add-back)	880.8M	1.13B	1.24B	1.18B	1.19B	1.77B	2.17B	2.13B	2.17B	2.35B
EBIT	2.18B	2.8B	3.1B	3.1B	3.41B	4.77B	7.84B	7.35B	5.33B	4.92B
Net Interest Income+	-135.2M	-184.2M	-155.2M	-127.7M	30.4M	-202M	-230M	-166M	14M	-161M
Interest Income	4.6M	200K	7.5M	9.2M	139M	71M	11M	41M	303M	117M
Interest Expense	139.8M	184.4M	162.7M	136.9M	108.6M	273M	241M	207M	289M	278M
Other Income/Expense	-378.3M	-376M	-210.7M	-108.2M	-57.1M	183M	-452M	-390M	-235M	-538M
Pretax Income+	2.04B	2.61B	2.94B	2.96B	3.31B	4.5B	7.6B	7.15B	5.04B	4.65B
Pretax Margin %	0.14%	0.15%	0.16%	0.17%	0.18%	0.2%	0.26%	0.27%	0.21%	0.19%
Income Tax+	292.7M	457.9M	469M	555.6M	873M	849M	1.25B	818M	823M	747M
Effective Tax Rate %	1.27%	0.98%	0.85%	0.9%	0.77%	0.81%	0.85%	1.01%	0.94%	0.84%
Net Income+	2.6B	2.55B	2.49B	2.65B	2.56B	3.65B	6.43B	7.21B	4.76B	3.9B
Net Margin %	0.18%	0.15%	0.14%	0.16%	0.14%	0.16%	0.22%	0.27%	0.2%	0.16%
Net Income Growth %	-0%	-0.02%	-0.02%	0.06%	-0.04%	0.43%	0.76%	0.12%	-0.34%	-0.18%
Net Income (Continuing)	1.75B	2.15B	2.47B	2.41B	2.43B	3.65B	6.35B	6.33B	4.22B	3.9B
Discontinued Operations	850.2M	400.3M	22.3M	244.6M	124.9M	0	86M	881M	543M	0
Minority Interest	73.7M	74M	9.6M	12.3M	11.3M	11M	10M	8M	4M	7M
EPS (Diluted)+	4.74	3.65	3.53	3.73	3.43	4.89	8.61	9.64	6.38	5.29
EPS Growth %	0.31%	-0.23%	-0.03%	0.06%	-0.08%	0.43%	0.76%	0.12%	-0.34%	-0.17%
EPS (Basic)	4.81	3.69	3.58	3.78	3.48	4.97	8.77	9.80	6.44	5.33
Diluted Shares Outstanding	708.5M	699.8M	706.1M	710.2M	725.5M	718.7M	736.8M	737.1M	743.1M	737.2M
Basic Shares Outstanding	698.1M	691.2M	695.8M	700.6M	715M	706.2M	714.6M	725.1M	736.5M	731M
Dividend Payout Ratio	0.14%	0.16%	0.15%	0.16%	0.21%	0.17%	0.12%	0.11%	0.17%	0.2%

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	7.84B	6.67B	6.85B	7.09B	25.6B	13.8B	11.65B	15.88B	13.94B	9.5B
Cash & Short-Term Investments	790.8M	963.7M	630.3M	787.8M	19.91B	6.04B	2.59B	6B	5.86B	2.08B
Cash Only	790.8M	963.7M	630.3M	787.8M	19.91B	6.04B	2.59B	6B	5.86B	2.08B
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	2.99B	3.19B	3.52B	3.11B	3.27B	4.81B	5.44B	5.06B	4.64B	4.39B
Days Sales Outstanding	75.49	68.88	70.13	66.62	66.6	78.79	67.45	69.38	70.85	67.11
Inventory	1.57B	1.71B	1.84B	1.63B	1.63B	2.29B	2.77B	2.77B	2.59B	2.33B
Days Inventory Outstanding	88.07	83.2	82.96	78.94	74.97	85.29	87.81	96.53	96.06	87.96
Other Current Assets	2.49B	805.9M	857.1M	1.56B	787.6M	665M	82M	1.36B	71M	79M
Total Non-Current Assets+	40.39B	38.63B	39.8B	40.74B	36.48B	62.36B	71.54B	68.47B	70.55B	68.05B
Property, Plant & Equipment	2.3B	2.35B	2.45B	2.25B	3.07B	4.2B	4.83B	4.59B	5.61B	6.07B
Fixed Asset Turnover	6.27x	7.17x	7.47x	7.58x	5.84x	5.30x	6.10x	5.80x	4.26x	3.93x
Goodwill	21.01B	23.83B	25.14B	22.58B	22.71B	35.42B	41.18B	37.28B	41.61B	40.5B
Intangible Assets	10.55B	11.82B	11.67B	10.28B	9.75B	21.28B	22.84B	19.82B	20.75B	18.57B
Long-Term Investments	401.4M	170.1M	45.4M	38.3M	33.7M	27M	1.32B	2.16B	1.7B	1.81B
Other Non-Current Assets	6.12B	461.2M	492.9M	5.59B	923.4M	1.43B	1.36B	4.61B	896M	1.09B
Total Assets+	48.22B	45.3B	46.65B	47.83B	62.08B	76.16B	83.18B	84.35B	84.49B	77.54B
Asset Turnover	0.30x	0.37x	0.39x	0.36x	0.29x	0.29x	0.35x	0.32x	0.28x	0.31x
Asset Growth %	0.3%	-0.06%	0.03%	0.03%	0.3%	0.23%	0.09%	0.01%	0%	-0.08%
Total Current Liabilities+	6.17B	6.87B	4.79B	4.84B	4.93B	7.4B	8.14B	8.39B	8.27B	6.8B
Accounts Payable	1.39B	1.49B	1.51B	1.5B	1.51B	2.05B	2.57B	1.86B	1.77B	1.75B
Days Payables Outstanding	77.92	72.28	68.05	72.36	69.73	76.24	81.53	64.8	65.4	66.17
Short-Term Debt	845.2M	2.59B	194.7M	51.8M	370.2M	200M	215M	758M	1.88B	505M
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	2.22B	954.7M	978.5M	1.41B	921.1M	1.93B	1.59B	2.48B	1.4B	1.34B
Current Ratio	1.27x	0.97x	1.43x	1.47x	5.19x	1.86x	1.43x	1.89x	1.68x	1.40x
Quick Ratio	1.02x	0.72x	1.05x	1.13x	4.86x	1.55x	1.09x	1.56x	1.37x	1.05x
Cash Conversion Cycle	85.63	79.81	85.04	73.2	71.85	87.83	73.74	101.11	101.51	88.9
Total Non-Current Liabilities+	18.29B	15.34B	15.49B	14.76B	26.87B	28.98B	29.87B	25.87B	22.72B	21.19B
Long-Term Debt	12.03B	9.67B	10.33B	9.69B	21.52B	21.19B	22.17B	19.09B	16.71B	15.5B
Capital Lease Obligations	0	15.2M	0	0	652.2M	785M	889M	772M	954M	968M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	6.19B	5.58B	5.06B	4.97B	4.59B	6.8B	6.6B	5.79B	4.81B	4.49B
Total Liabilities	24.46B	22.22B	20.28B	19.61B	31.8B	36.38B	38.01B	34.26B	31B	27.99B
Total Debt+	12.87B	12.27B	10.52B	9.74B	22.53B	22.18B	23.27B	20.62B	19.54B	17.15B
Net Debt	12.08B	11.31B	9.89B	8.95B	2.61B	16.14B	20.69B	14.62B	13.67B	15.07B
Debt / Equity	0.54x	0.53x	0.40x	0.35x	0.74x	0.56x	0.52x	0.41x	0.37x	0.35x
Debt / EBITDA	3.90x	2.98x	2.40x	2.29x	4.95x	3.64x	2.28x	2.13x	2.62x	2.28x
Net Debt / EBITDA	3.66x	2.75x	2.25x	2.11x	0.57x	2.65x	2.02x	1.51x	1.84x	2.00x
Interest Coverage	17.29x	16.20x	19.36x	22.43x	30.96x	15.79x	33.40x	36.41x	18.27x	18.65x
Total Equity+	23.76B	23.08B	26.37B	28.23B	30.28B	39.78B	45.18B	50.09B	53.49B	49.55B
Equity Growth %	0.01%	-0.03%	0.14%	0.07%	0.07%	0.31%	0.14%	0.11%	0.07%	-0.07%
Book Value per Share	33.54	32.98	37.34	39.74	41.74	55.35	61.32	67.96	71.98	67.21
Total Shareholders' Equity	23.69B	23B	26.36B	28.21B	30.27B	39.77B	45.17B	50.08B	53.49B	49.54B
Common Stock	8M	8.1M	8.1M	8.2M	8.4M	9M	9M	9M	9M	9M
Retained Earnings	21.01B	20.7B	22.81B	25.16B	24.17B	27.16B	32.83B	39.2B	41.07B	44.19B
Treasury Stock	0	0	0	0	0	0	0	0	0	-8.16B
Accumulated OCI	-2.31B	-3.02B	-1.99B	-2.79B	-3.07B	-368M	-1.03B	-2.87B	-1.75B	-3.22B
Minority Interest	73.7M	74M	9.6M	12.3M	11.3M	11M	10M	8M	4M	7M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	3.8B	3.52B	3.48B	4.02B	3.95B	6.21B	8.36B	8.52B	7.16B	6.69B
Operating CF Margin %	0.26%	0.21%	0.19%	0.24%	0.22%	0.28%	0.28%	0.32%	0.3%	0.28%
Operating CF Growth %	0.01%	-0.07%	-0.01%	0.16%	-0.02%	0.57%	0.35%	0.02%	-0.16%	-0.07%
Net Income	2.6B	2.15B	2.47B	2.65B	2.43B	3.65B	6.35B	7.21B	4.22B	3.9B
Depreciation & Amortization	1.05B	1.13B	1.24B	1.31B	1.19B	1.77B	2.17B	2.22B	2.17B	2.35B
Stock-Based Compensation	139M	129.8M	139.4M	151.4M	158.8M	187M	184M	295M	306M	288M
Deferred Taxes	-151.3M	-383.9M	-426.9M	-195.1M	-415.2M	-462M	-318M	-559M	0	0
Other Non-Cash Items	112.7M	773.6M	410.2M	197.2M	709.4M	457M	601M	830M	864M	-117M
Working Capital Changes	51.4M	-279.2M	-353M	-90.1M	-123.2M	605M	-658M	-1.52B	-393M	266M
Change in Receivables	-52.1M	-183.1M	-161.4M	-58.3M	-156.4M	-264M	-611M	-477M	322M	331M
Change in Inventory	119.7M	9.4M	-27.4M	-143.3M	-21.9M	-123M	-502M	-486M	185M	147M
Change in Payables	103.9M	78.1M	-54.4M	225.8M	18.1M	227M	549M	5M	-149M	19M
Cash from Investing+	-14.95B	-5.24B	-843.4M	-2.95B	-1.24B	-21.24B	-12.99B	-2.23B	-7.08B	-1.98B
Capital Expenditures	-512.9M	-589.6M	-570.7M	-584M	-635.5M	-791M	-1.29B	-1.15B	-1.38B	-1.39B
CapEx % of Revenue	0.04%	0.03%	0.03%	0.03%	0.04%	0.04%	0.04%	0.04%	0.06%	0.06%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-89M	-4.65B	-272.7M	-65M	28.9M	26M	50M	60M	23M	-511M
Cash from Financing+	9.05B	2.04B	-3.1B	-797M	16.37B	1.01B	1.29B	-2.57B	-273M	-8.38B
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-354.1M	-399.8M	-378.3M	-433.4M	-526.7M	-615M	-742M	-818M	-821M	-768M
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-3.3M	-512.3M	-124.2M	-17.6M	-274.7M	-29M	-16M	-95M	2.11B	-131M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	3.29B	2.93B	2.91B	3.44B	3.32B	5.42B	7.06B	7.37B	5.78B	5.3B
FCF Margin %	0.23%	0.17%	0.16%	0.2%	0.19%	0.24%	0.24%	0.28%	0.24%	0.22%
FCF Growth %	-0%	-0.11%	-0.01%	0.18%	-0.04%	0.63%	0.3%	0.04%	-0.22%	-0.08%
FCF per Share	4.64	4.19	4.12	4.84	4.57	7.54	9.59	9.99	7.78	7.18
FCF Conversion (FCF/Net Income)	1.46x	1.38x	1.40x	1.52x	1.55x	1.70x	1.30x	1.18x	1.50x	1.72x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	11%	10.9%	10.08%	9.71%	8.74%	10.41%	15.14%	15.13%	9.2%	7.57%
Return on Invested Capital (ROIC)	6.07%	6.38%	6.69%	6.27%	7.2%	7.28%	9.92%	8.66%	6%	5.9%
Gross Margin	54.83%	55.58%	55.81%	55.75%	55.74%	55.98%	60.95%	60.76%	58.74%	59.5%
Net Margin	17.99%	15.13%	13.6%	15.55%	14.28%	16.36%	21.84%	27.06%	19.94%	16.33%
Debt / Equity	0.54x	0.53x	0.40x	0.35x	0.74x	0.56x	0.52x	0.41x	0.37x	0.35x
Interest Coverage	17.29x	16.20x	19.36x	22.43x	30.96x	15.79x	33.40x	36.41x	18.27x	18.65x
FCF Conversion	1.46x	1.38x	1.40x	1.52x	1.55x	1.70x	1.30x	1.18x	1.50x	1.72x
Revenue Growth	-27.52%	16.97%	8.57%	-6.99%	5.06%	24.41%	32.17%	-9.54%	-10.33%	-0.06%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Revenue from Contract with Customer, Measurement, Recurring	-	-	-	13.72B	12.31B	15.98B	21.8B	23.72B	18.68B	19.37B
Revenue from Contract with Customer, Measurement, Recurring Growth	-	-	-	-	-10.32%	29.82%	36.41%	8.82%	-21.23%	3.66%
Revenue from Contract with Customer, Measurement, Nonrecurring	-	-	-	6.17B	5.6B	6.31B	7.66B	7.75B	5.21B	4.51B
Revenue from Contract with Customer, Measurement, Nonrecurring Growth	-	-	-	-	-9.17%	12.53%	21.44%	1.25%	-32.83%	-13.42%
Diagnostics	-	-	5.84B	-	-	-	-	-	-	-
Diagnostics Growth	-	-	-	-	-	-	-	-	-	-
Life Sciences	-	-	5.71B	-	-	-	-	-	-	-
Life Sciences Growth	-	-	-	-	-	-	-	-	-	-
Environmental & Applied Solutions	-	-	3.97B	-	-	-	-	-	-	-
Environmental & Applied Solutions Growth	-	-	-	-	-	-	-	-	-	-
Dental	2.74B	-	2.81B	-	-	-	-	-	-	-
Dental Growth	-	-	-	-	-	-	-	-	-	-
Research and medical products	-	10.37B	-	-	-	-	-	-	-	-
Research and medical products Growth	-	-	-	-	-	-	-	-	-	-
Dental products	-	2.79B	-	-	-	-	-	-	-	-
Dental products Growth	-	-	-	-	-	-	-	-	-	-
Analytical And Physical Instrumentation	-	2.09B	-	-	-	-	-	-	-	-
Analytical And Physical Instrumentation Growth	-	-	-	-	-	-	-	-	-	-
Product Identification	-	1.64B	-	-	-	-	-	-	-	-
Product Identification Growth	-	-	-	-	-	-	-	-	-	-
Life Sciences And Diagnostics	8.21B	-	-	-	-	-	-	-	-	-
Life Sciences And Diagnostics Growth	-	-	-	-	-	-	-	-	-	-
Environmental	3.64B	-	-	-	-	-	-	-	-	-
Environmental Growth	-	-	-	-	-	-	-	-	-	-
Industrial Technologies	3.32B	-	-	-	-	-	-	-	-	-
Industrial Technologies Growth	-	-	-	-	-	-	-	-	-	-
Test And Measurement	2.65B	-	-	-	-	-	-	-	-	-
Test And Measurement Growth	-	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Other developed markets	8.38B	6.76B	7.45B	8B	7.93B	9.74B	12.71B	12.64B	1.27B	11.14B
Other developed markets Growth	-	-19.34%	10.21%	7.37%	-0.81%	22.84%	30.50%	-0.55%	-89.95%	777.40%
North America	9.07B	6.38B	6.84B	7.37B	6.66B	8.62B	11.28B	13.37B	9.96B	9.93B
North America Growth	-	-29.71%	7.22%	7.85%	-9.69%	29.38%	30.95%	18.45%	-25.47%	-0.34%
CHINA	1.99B	1.8B	2.01B	2.36B	2.31B	2.69B	3.98B	4B	-	2.81B
CHINA Growth	-	-9.58%	11.81%	17.19%	-2.10%	16.47%	47.88%	0.68%	-	-
High-growth markets	-	-	-	-	-	-	-	-	7.19B	-
High-growth markets Growth	-	-	-	-	-	-	-	-	-	-
Western Europe	-	-	-	-	-	-	-	-	5.47B	-
Western Europe Growth	-	-	-	-	-	-	-	-	-	-
GERMANY	1.12B	1.08B	1.16B	1.25B	1.01B	1.24B	1.48B	1.46B	-	-
GERMANY Growth	-	-3.46%	7.10%	7.35%	-18.77%	22.21%	19.71%	-1.42%	-	-
JAPAN	-	864.7M	872.1M	918.7M	-	-	-	-	-	-
JAPAN Growth	-	-	0.86%	5.34%	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

Danaher Corporation (DHR) has a price-to-earnings (P/E) ratio of 45.3x. This suggests investors expect higher future growth.

Growth & Financials

Danaher Corporation (DHR) reported $24.27B in revenue for fiscal year 2024. This represents a 51% increase from $16.09B in 2011.

Danaher Corporation (DHR) saw revenue decline by 0.1% over the past year.

Yes, Danaher Corporation (DHR) is profitable, generating $3.50B in net income for fiscal year 2024 (16.3% net margin).

Dividend & Returns

Yes, Danaher Corporation (DHR) pays a dividend with a yield of 0.43%. This makes it attractive for income-focused investors.

Danaher Corporation (DHR) has a return on equity (ROE) of 7.6%. This is below average, suggesting room for improvement.

Danaher Corporation (DHR) generated $5.02B in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...